The OECD Nuclear Energy Agency (NEA) is conducting an international survey to gather expert insights on the current status of radioligand therapy (RLT) and its integration into cancer care, as well as to forecast future demand by estimating patient eligibility across cancer indications and treatment scenarios.
The survey is part of a broader effort by the NEA to provide evidence-based policy recommendations and to address current and emerging challenges in the global nuclear medicine supply chain. The results will contribute to an NEA report scheduled to be published next year.
Survey 1: Current status of RLT and RLI
This survey collects information on the clinical use, therapeutic efficacy, innovation pipelines and healthcare system readiness for delivering radioligand therapy (RLT) and radioligand imaging (RLI).
Surveys 2 and 3: Patient Eligibility for RLT
These two surveys aim to estimate the number of patients eligible for RLT, including those eligible under emerging radiopharmaceutical approaches, to help forecast future demand.
Respondents are invited to provide information based on their expertise on behalf of their country, region or institution. Where exact data are not available, estimates or qualitative assessments are welcome.
The responses to these survey are anonymous and will be analysed by the NEA. For any questions and comments, please send an email to: medical_isotopes@oecd-nea.org
